Fox S - Search Results

1

Psychiatric comorbidities in dystonia: emerging concepts.

Zurowski M, McDonald WM, Fox S, Marsh L. Zurowski M, et al. Among authors: fox s. Mov Disord. 2013 Jun 15;28(7):914-20. doi: 10.1002/mds.25501. Mov Disord. 2013. PMID: 23893448 Free PMC article. Review.

2

Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Gomez-Ramirez J, Johnston TH, Visanji NP, Fox SH, Brotchie JM. Gomez-Ramirez J, et al. Mov Disord. 2006 Jun;21(6):839-46. doi: 10.1002/mds.20828. Mov Disord. 2006. PMID: 16532454

3

Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure.

Fox SH, Lang AE, Brotchie JM. Fox SH, et al. Mov Disord. 2006 Oct;21(10):1578-94. doi: 10.1002/mds.20936. Mov Disord. 2006. PMID: 16874752 Review.

4

Prevalence of repetitive and reward-seeking behaviors in Parkinson disease.

Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T, Fox S, Lang AE, Miyasaki J. Voon V, et al. Among authors: fox s. Neurology. 2006 Oct 10;67(7):1254-7. doi: 10.1212/01.wnl.0000238503.20816.13. Epub 2006 Sep 6. Neurology. 2006. PMID: 16957130 Clinical Trial.

5

Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM, Fox SH. Visanji NP, et al. Mov Disord. 2006 Nov;21(11):1879-91. doi: 10.1002/mds.21073. Mov Disord. 2006. PMID: 16960862

6

Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease.

Voon V, Thomsen T, Miyasaki JM, de Souza M, Shafro A, Fox SH, Duff-Canning S, Lang AE, Zurowski M. Voon V, et al. Among authors: fox sh. Arch Neurol. 2007 Feb;64(2):212-6. doi: 10.1001/archneur.64.2.212. Arch Neurol. 2007. PMID: 17296836

7

Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease.

Thomsen TR, Galpern WR, Asante A, Arenovich T, Fox SH. Thomsen TR, et al. Mov Disord. 2007 Nov 15;22(15):2268-73. doi: 10.1002/mds.21730. Mov Disord. 2007. PMID: 17876852 Clinical Trial.

8

Levodopa-related motor complications--phenomenology.

Fox SH, Lang AE. Fox SH, et al. Mov Disord. 2008;23 Suppl 3:S509-14. doi: 10.1002/mds.22021. Mov Disord. 2008. PMID: 18781677 Review.

9

Serotonin and Parkinson's disease: On movement, mood, and madness.

Fox SH, Chuang R, Brotchie JM. Fox SH, et al. Mov Disord. 2009 Jul 15;24(9):1255-66. doi: 10.1002/mds.22473. Mov Disord. 2009. PMID: 19412960 Review.

10

Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.

Johnston TH, van der Meij A, Brotchie JM, Fox SH. Johnston TH, et al. Mov Disord. 2010 Jul 30;25(10):1379-90. doi: 10.1002/mds.23069. Mov Disord. 2010. PMID: 20310030

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,582 results

Search Page

Filters